articleTop 1% cited
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
European Urology · 2016 · Vol. 71(4) · pp. 630–642
Philip Cornford✉(Royal Liverpool and Broadgreen University Hospital NHS Trust)Joaquim Bellmunt(Dana-Farber Cancer Institute)M. Bolla(Centre Hospitalier Universitaire de Grenoble)Erik BriersMaria De Santis(University of Warwick)Tobias Gross(University of Bern)Ann Henry(St James's University Hospital)Steven Joniau(KU Leuven)Thomas Lam(University of Aberdeen)Malcolm D. Mason(Velindre Cancer Centre)Henk G. van der Poel(The Netherlands Cancer Institute)Theodorus van der Kwast(Erasmus University Rotterdam)Olivier Rouvière(Hospices Civils de Lyon)Thomas Wiegel(University Hospital Ulm)Nicolas Mottet(Centre Hospitalier Universitaire de Saint-Étienne)
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentCancer, Lipids, and MetabolismMedicineProstate cancerAndrogen deprivation therapyDocetaxelProstatectomyBrachytherapyRadiation therapyUrologyProstate-specific antigenOncology
MeSH terms
Abiraterone AcetateDocetaxelAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBrachytherapyCarcinomaCryosurgeryHumansMaleNeoplasm MetastasisNeoplasm Recurrence, LocalNitrilesPhenylthiohydantoinProstatic Neoplasms
Citations
1,439
FWCI
148.37
field-weighted impact
References
108
Percentile
100%
vs. same field & year
Citations per year
Cited by
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
European Urology · 2020 · 1,110 citations
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
European Urology · 2017 · 639 citations
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2020 · 931 citations
References
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2015 · 1,334 citations
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
International Journal of Radiation Oncology*Biology*Physics · 2006 · 2,705 citations
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
European Urology · 2013 · 1,348 citations
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Journal of Clinical Oncology · 2008 · 2,225 citations
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2012 · 1,374 citations
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
European Urology · 2016 · 3,241 citations
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
JNCI Journal of the National Cancer Institute · 2002 · 1,654 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.